Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Aktuální cena Amgen na trhu je 8 366,17 Kč s 24hodinovým objemem obchodování 21,92B Kč. Tržní kapitalizace aktiva je 4,51T Kč po změně o 4.48% za poslední den.
Tokenizovaný Amgen se obchoduje za 8 437,37 Kč, s tokenizovanou tržní kapitalizací 84,02K Kč a 24hodinovým objemem obchodování 17,94M Kč. Tokenizované aktivum se posunulo o 15.20% za posledních 24 hodin.